Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: A study of the German testicular cancer study group

Journal of Clinical Oncology

Volumn 22, Issue 1, 2004, Pages 108-114

  Kollmannsberger, C ^a   Beyer, J ^a   Liersch, R ^a   Schoeffski, P ^a   Metzner, B ^a   Rick, O ^a   Hartmann, J T ^a   Stengele, K ^a   Hohloch, K ^a   Spott, C ^a   Kanz, L ^a   Bokemeyer, C ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GEMCITABINE; OXALIPLATIN;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG ACTIVITY; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FOLLOW UP; GERM CELL TUMOR; HUMAN; PRIORITY JOURNAL; REFRACTORY PERIOD; RELAPSE; REMISSION; STEM CELL TRANSPLANTATION; SURVIVAL TIME; TREATMENT FAILURE; TUMOR LOCALIZATION;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS, GERM CELL AND EMBRYONAL; ORGANOPLATINUM COMPOUNDS; TESTICULAR NEOPLASMS; TREATMENT OUTCOME;

EID: 3142577828     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.06.068     Document Type: Article

References (26)

1. Einhorn LH: Treatment of testicular cancer: A new and improved model. J Clin Oncol 8:1777-1781, 1990
2. Bosl GJ, Motzer RJ: Medical progress: Testicular germ-cell cancer. N Engl J Med 337:242-253, 1997
3. Porcu P, Bhatia S, Einhorn LH: Results of treatment after relapse from high-dose chemotherapy in germ cell tumors. J Clin Oncol 18:1181-1186, 2000
4. Miller JC, Einhorn LH: Phase II study of daily oral etoposide in refractory germ cell tumors. Semin Oncol 17:36-39, 1990
5. Motzer RJ, Bajorin D, Schwartz LH, et al: Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J Clin Oncol 12:2277-2283, 1994
6. Bokemeyer C, Beyer J, Metzner B, et al: Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Ann Oncol 7:31-34, 1996
7. Bokemeyer C, Gerl A, Schöffski P, et al: Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer. J Clin Oncol 17:512-516, 1999
8. Einhorn LH, Stender MJ, Williams SD: Phase II trial of gemcitabine in refractory germ cell tumors. J Clin Oncol 17:509-511, 1999
9. Kollmannsberger C, Rick O, Derigs HG, et al: Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: A study of the German Testicular Cancer Study Group. J Clin Oncol 20:2031-2037, 2002
10. Plunkett W, Huang P, Xu YZ, et al: Gemcitabine: Metabolism, mechanisms of action, and self-potentiation. Semin Oncol 22:3-10, 1995
11. Dunn TA, Schmoll HJ, Grünwald V, et al: Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell lines. Invest New Drugs 15:109-114, 1997
12. Fink D, Nebel S, Aebi S, et al: The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56:4881-4886, 1996
13. Faivre S, Raymond E, Woynarowski JM, et al: Supraadditive effect of 2′, 2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol 44:117-123, 1999
14. Mavroudis D, Kourousis C, Kakolyris S, et al: Phase I study of the gemcitabine/oxaliplatin combination in patients with advanced solid tumors: A preliminary report. Semin Oncol 27:25-30, 2000
15. Louvet C, Andre T, Lledo G, et al: Gemcitabine-oxaliplatin (GEMOX) combination in advanced pancreatic carcinoma (APC): A Gercor Multicenter Phase II Study. Proc Am Soc Clin Oncol 20:127, 2001 (abstr 506)
16. Franciosi V, Barbieri R, Vasini G, et al: Feasible combination of gemcitabine and oxaliplatin (GEM-OXAL) in patients with advanced non-small-cell lung cancer: Preliminary results of a phase II study. Proc Am Soc Clin Oncol 20:263, 2001 (abstr 2804)
17. Maindrault-Goebel F, de Gramont A, Louvet C, et al: Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Ann Oncol 11:1477-1483, 2000
18. Maindrault-Goebel F, de Gramont A, Louvet C, et al: High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur J Cancer 37:1000-1005, 2001
19. Nichols CR, Tricot G, Williams SD, et al: Dose-intensive chemotherapy in refractory germ cell cancer: A phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 7:932-939, 1989
20. Beyer J, Kramar A, Mandanas R, et al: High-dose chemotherapy as salvage treatment in germ cell tumors: A multivariate analysis of prognostic variables. J Clin Oncol 14:2638-2645, 1996
21. Miller AB, Hoodgstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-211, 1981
22. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
23. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
24. Hinton S, Catalano PJ, Einhorn L, et al: Phase II trial of paclitaxel and gemcitabine in refractory germ cell tumors. J Clin Oncol 20:1859-1863, 2001
25. Pizzocaro G, Nicolai N, Salvioni R, et al: Paclitaxel, cisplatin and gemcitabine (TPG) third line therapy in metastatic germ cell tumors (GCT) of the testis. Proc Am Soc Clin Oncol 20:194, 2001 (abstr 773)
26. Brienza S, Vignoud J, Itzhaki M, et al: Oxaliplatin (LOHP): Global safety in 682 patients. Proc Am Soc Clin Oncol 14:209, 1995 (abstr 513)